8-K
filed April 1, 2026, 7:59 PM ET
ticker CVKD
CIK 0001937993
other material
confidence high
sentiment neutral
materiality 0.65
Cadrenal Therapeutics receives $2.5M gross proceeds from warrant exercise, issues new warrants
Cadrenal Therapeutics, Inc.
- Existing warrant holder exercises 571,430 shares at reduced price of $4.50 per share, yielding $2.5M gross proceeds.
- Company issues new Series B-1 (5-year term) and Series B-2 (18-month term) warrants to purchase 571,430 shares each at $4.50.
- Placement agent H.C. Wainwright receives 7% cash fee ($175k) and warrants for 37,143 shares at $5.625.
- Expected closing on April 1, 2026; net proceeds used for working capital.
- Company agrees to file resale registration statement for new warrant shares within 30 days.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-26-038014
- form_type
- 8-K
- ticker
- CVKD
- cik
- 0001937993
- company_name
- Cadrenal Therapeutics, Inc.
- filed_at
- 2026-04-01T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.299040+00:00
- generated_at
- 2026-05-15T08:01:44.301965+00:00
- sec_items
- ["1.01", "3.02", "3.03", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-26-038014
- json_url
- https://secwatch.observer/filing/0001213900-26-038014.json
- markdown_url
- https://secwatch.observer/filing/0001213900-26-038014.md
- text_url
- https://secwatch.observer/filing/0001213900-26-038014.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/0001213900-26-038014-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/ea0284507-8k_cadrenal.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
XWIN
XMax raises $3.6M via private placement of 486,500 shares at $7.347/share
XMax Inc.
June 2, 2026, 4:30 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).
Filing page
SEC filing
GNK
Genco Shipping amends shareholder rights plan, eliminates 'Acting in Concert' definition
GENCO SHIPPING & TRADING LTD
June 2, 2026, 6:01 AM ET
other_material
Items 1.01, 3.03, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.03, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
On June 2, 2026, Genco Shipping & Trading Limited (the “ Company ”) entered into the Third Amendment to Shareholders Rights Agreement (the “ Third Amendment ”) to amend the Shareholder Rights Agreement, dated as of October 1, 2025 between the Company and Computershare Inc., as amended to date (the “ Rights Agreement ”).
Filing page
SEC filing
TPST
Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73
Tempest Therapeutics, Inc.
June 1, 2026, 7:13 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock
Filing page
SEC filing
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent
Filing page
SEC filing
CITR
CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights
CitroTech Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock
Filing page
SEC filing
SAGU
Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE
Shreya Acquisition Group
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference
Filing page
SEC filing
XRN
Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP
Chiron Real Estate Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.
Filing page
SEC filing
PBT
Court approves trust indenture amendments eliminating 75% supermajority requirement
PERMIAN BASIN ROYALTY TRUST
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.03, 5.03, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.03, 9.01
same event type: other_material
similar materiality
This filing
On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
Comparable filing
Argent Trust Company, the trustee of the Trust, entered into Amendment No. 2 to the Amended and Restated Trust Indenture of Permian Basin Royalty Trust dated May 8, 2026 (the “Amendment”) implementing the modifications approved by the Court.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.